Paul Koller

2 weeks ago | onlinelibrary.wiley.com | Vaibhav Agrawal |Shukaib Arslan |Hoda Pourhassan |Paul Koller

CONFLICT OF INTEREST STATEMENT The authors have no conflicts of interest to declare. REFERENCES 1, , , , . Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood. 2012; 119(1): 34–43. 2, . Management of adults with T-cell lymphoblastic leukemia. Blood. 2017; 129(9): 1134–1142. 3, , , , , , et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009; 10(2): 147–156.

Nov 21, 2024 | jamanetwork.com | Elias Jabbour |Vivian G. Oehler |Paul Koller

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial Podcast (18:46) 0:00 / 0:00 Key Points Question What is the pharmacokinetic profile of olverembatinib, which is approved in China, in non-Chinese individuals, and is it a safe and efficacious treatment option for patients with relapsed/refractory chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia, including those previously...

May 29, 2024 | onlinelibrary.wiley.com | Tamer Othman |Paul Koller |Hoda Pourhassan |Vaibhav Agrawal

Corresponding Author Ibrahim Aldoss Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA Correspondence Ibrahim Aldoss, Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 E Duarte Road, Duarte, CA 91010, USA. Email: [email protected] for more papers by this author